Skip to main content
. Author manuscript; available in PMC: 2025 Jun 3.
Published in final edited form as: Mol Cancer Ther. 2024 Dec 3;23(12):1801–1814. doi: 10.1158/1535-7163.MCT-24-0369

Figure 4. RB1 deficiency blunts cell cycle suppression and IFN response to combination palbociclib-trametinib treatment.

Figure 4.

A. qPCR analysis of CCNA2, CCNB1, and EZH2 cell cycle genes in HT1080-sgCtrl/sgRB cells treated with DMSO or CDK4/6i (Palbociclib, 100 nM) and MEKi (Trametinib, 25 nM) in combination. B. qPCR analysis of CCNA2, CCNB1, and EZH2 cell cycle genes in HT1080-sgCtrl/sgRB tumor tissues treated with vehicle or CDK4/6i (Palbociclib, 100 mg/kg) and MEKi (Trametinib, 0.5 mg/kg) in combination. C. qPCR analysis of STAT2, IRF9 and HLA-A immune-related genes in HT1080-sgCtrl/sgRB cells treated with DMSO or CDK4/6i (Palbociclib, 100 nM) and MEKi (Trametinib, 25 nM) for 48 h. D. qPCR analysis of STAT2, IRF9, and HLA-A immune-related genes in HT1080-sgCtrl/sgRB tumor tissues treated with vehicle or CDK4/6i (Palbociclib, 100 mg/kg) and MEKi (Trametinib, 0.5 mg/kg) in combination. E. ISRE-mCherry IFN reporter assay in HT1080-sgCtrl/sgRB cells treated with DMSO, CDK4/6i (Palbociclib, 100 nM), MEKi (Trametinib, 25 nM), or CDK4/6i and MEKi in combination for 72 h. Scale bar = 100 μm. Data displayed as mean ± SD in triplicate. * p < 0.05, ** p < 0.01, *** p < 0.001 **** p < 0.0001 as determined by two-way ANOVA.